Turmeric supplementation has measurable energizing and anti-inflammatory effects.
the verdict
CONTESTED PARTIAL
refutedsupported
the weight of evidence
9 sources for · 1 against
Extensive clinical literature and systematic reviews substantiate that turmeric and curcumin supplementation possess measurable anti-inflammatory effects by lowering inflammatory markers such as CRP, TNF-alpha, and IL-6, though some specific formulations or cohorts report mixed results. However, the provided evidence base lacks documentation or evaluation regarding any measurable energizing effects.
Abstract Context Chronic inflammation is a major contributor to the development of noncommunicable diseases. Curcumin, a bioactive polyphenol from turmeric, is a well-known anti-inflammatory agent in preclinical research. Clinical evidence remains inconclusive because of discrepancies regarding optimal dosage, duration, and formulation of curcumin. Objective The aim of this systematic review, conducted and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and checklist, was to evaluate the efficacy of curcumin supplementation on systemic inflammatory mediators, comparing dose, duration, and bioavailability status of interventions. Data Sources The Medline, CINAHL, EMBASE, Scopus, and Cochrane literature databases were searched from 1980 to May-end 2019. Randomized controlled trials investigating effects of dietary curcumin on inflammatory mediators in humans not receiving anti-inflammatory treatment were eligible for inclusion. Two authors independently assessed titles and abstracts of identified articles for potential eligibility and respective, retrieved, full-text articles; disagreements were resolved by a third author. Evidence quality was critically appraised using the Quality Criteria Checklist for Primary Research. Data Extraction Thirty-two trials (N = 2,038 participants) were included and 28 were meta-analyzed using a random-effects model; effect sizes were expressed as Hedges’ g (95%CI). Data Analysis Pooled data (reported here as weighted mean difference [WMD]; 95%CI) showed a reduction in C-reactive protein (−1.55 mg/L; −1.81 to −1.30), interleukin-6 (−1.69 pg/mL, −2.56 to −0.82), tumor necrosis factor α (−3.13 pg/mL; −4.62 to −1.64), IL-8 (−0.54 pg/mL; −0.82 to −0.28), monocyte chemoattractant protein-1 (−2.48 pg/mL; −3.96 to −1.00), and an increase in IL-10 (0.49 pg/mL; 0.10 to 0.88), with no effect on intracellular adhesion molecule-1. Conclusion These findings provide evidence for the anti-inflammatory effects of curcumin and support further investigation to confirm dose, duration, and formulation to optimize anti-inflammatory effects in humans with chronic inflammation. Systematic Review Registration PROSPERO registration no. CRD42019148682.
<h4>Background</h4>Nanocurcumin has been developed to overcome the poor bioavailability of conventional curcumin and has been proposed as a potential adjunctive therapy for type 2 diabetes mellitus (T2DM). However, evidence regarding its clinical efficacy remains inconsistent. This systematic review and meta-analysis aimed to evaluate the effects of nanocurcumin supplementation on glycemic control, lipid profile, inflammatory markers and oxidative stress in patients with T2DM.<h4>Methods</h4>A systematic search of PubMed, Scopus and the Cochrane Library was conducted from inception to October 2025 to identify randomized controlled trials (RCTs) assessing nanocurcumin supplementation in adults with T2DM. Eligible studies compared nanocurcumin with placebo or no intervention and reported outcomes related to glycemic indices, lipid parameters, inflammatory markers or oxidative stress. Pooled effect sizes were calculated using a random-effects model and expressed as standardized mean differences (SMDs) with 95% confidence intervals (CIs). Between-study heterogeneity was assessed using the I<sup>2</sup> statistic.<h4>Results</h4>Seven RCTs involving 453 participants were included. Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05). No statistically significant reduction in C-reactive protein was observed (SMD: -0.78; 95% CI: -1.58 to 0.05). In contrast, nanocurcumin significantly increased total antioxidant capacity (SMD: 1.60; 95% CI: 0.93 to 2.31) and reduced malondialdehyde levels (SMD: -1.93; 95% CI: -3.19 to -0.66), indicating a robust antioxidative effect.<h4>Conclusions</h4>Current evidence suggests that short-term nanocurcumin supplementation does not significantly improve glycemic control, lipid profile or systemic inflammation in patients with T2DM.
This systematic review and meta‐analysis aimed to evaluate the effects of nanocurcumin supplementation on glycemic control, lipid profile, inflammatory markers and oxidative stress in patients with T2DM. Methods A systematic search of PubMed, Scopus and the Cochrane Library was conducted from inception to October 2025 to identify randomized controlled trials (RCTs) assessing nanocurcumin supplementation in adults with T2DM. Eligible studies compared nanocurcumin with placebo or no intervention and reported outcomes related to glycemic indices, lipid parameters, inflammatory markers or oxidative stress.
Curcumin, a polyphenolic compound derived from the rhizome of Curcuma longa (turmeric), has attracted considerable scientific interest over the past recent decades owing to its anti‐inflammatory, antioxidant, and hypoglycemic properties [ 9 , 10 , 11 , 12 , 13 ]. Experimental and clinical studies have demonstrated that curcumin reduces oxidative stress, improves lipid profiles, inhibits platelet aggregation and modulates insulin signalling, thereby mitigating several metabolic and vascular complications of diabetes [ 14 , 15 ].
(A) presents the overall summary of bias risk across all studies and (B) presents the domain‐specific assessment for each study. A green dot indicates a low risk of bias,
FIGURE 7 Leave‐one‐out sensitivity analysis of the pooled effects of nanocurcumin supplementation on glycemic control parameters, including (A) FBS and (B) HbA1C Levels. FIGURE 8 Leave‐one‐out sensitivity analysis of the pooled effects of nanocurcumin supplementation on biomarkers of inflammation and oxidative stress, including (A) C‐reactive protein (CRP), (B) total antioxidant capacity (TAC) and (C) malondialdehyde (MDA) levels. 3.3. Effect of Nanocurcumin on Primary Outcomes 3.3.1.
FIGURE 4 Forest plots illustrating the pooled effects of nanocurcumin supplementation on glycemic control parameters, including (A) fasting blood sugar (FBS) and (B) glycated haemoglobin (HbA1c). 3.3.6. HbA1c A random‐effects meta‐analysis involving 5 trials with a total of 336 participants (166 in the nanocurcumin group and 170 in the control group) showed no statistically significant difference in HbA1c levels following nanocurcumin supplementation [SMD: 0.19, 95% CI: (−1.26, 1.65), p = 0.79] (Figure 4 ). 3.3.7.
C‐Reactive Protein A random‐effects meta‐analysis that included 5 trials with a total of 303 participants (149 cases and 154 controls) found no significant difference in C‐reactive protein (CRP) levels after consuming nanocurcumin [SMD: −0.78, 95% CI: (−1.58, 0.05), p = 0.052] (Figure 5 ). FIGURE 5 Forest plots depicting the pooled effects of nanocurcumin supplementation on biomarkers of oxidative stress and inflammation, including (A) C‐reactive protein (CRP), (B) total antioxidant capacity (TAC) and (C) malondialdehyde (MDA) levels. 3.3.8.
Discussion This systematic review and meta‐analysis of seven randomized controlled trials provides a nuanced evaluation of the effects of nanocurcumin supplementation on a spectrum of clinical parameters in patients with T2DM. The principal finding of our study is that nanocurcumin, despite its enhanced bioavailability, did not confer statistically significant benefits on conventional glycemic indices (FBS and HbA1c), lipid profiles (total cholesterol, LDL‐C, HDL‐C and triglycerides) or the inflammatory marker CRP. However, it demonstrated preliminary evidence of antioxidative effects, significantly increasing TAC and reducing MDA levels.
Despite the lack of metabolic improvements, nanocurcumin demonstrated significant beneficial effects on oxidative stress, reflected by the marked increase in TAC and reduction in MDA. These findings are partially consistent with a recent meta‐analysis showing that curcumin supplementation improves multiple oxidative stress and inflammatory biomarkers, although not all parameters, such as total antioxidant capacity, consistently reach statistical significance [ 30 ].
Turmeric (Curcuma longa) has been extensively studied for its diverse pharmacological properties, including its potential role as an anticancer agent, antioxidant, and radioprotector. This review provides an overview of the chemical composition of turmeric, focusing on its main bioactive compounds, such as curcuminoids and volatile oils. Curcumin, the most abundant curcuminoid in turmeric, has been widely investigated for its various biological activities, including anti-inflammatory, antioxidant, and anticancer effects. Numerous in vitro and in vivo studies have demonstrated the ability of curcumin to modulate multiple signaling pathways involved in carcinogenesis, leading to inhibition of cancer cell proliferation, induction of apoptosis, and suppression of metastasis. Furthermore, curcumin has shown promising potential as a radioprotective agent by mitigating radiation-induced oxidative stress and DNA damage. Additionally, turmeric extracts containing curcuminoids have been reported to exhibit potent antioxidant activity, scavenging free radicals and protecting cells from oxidative damage. The multifaceted pharmacological properties of turmeric make it a promising candidate for the development of novel therapeutic strategies for cancer prevention and treatment, as well as for the management of oxidative stress-related disorders. However, further research is warranted to elucidate the underlying mechanisms of action and to evaluate the clinical efficacy and safety of turmeric and its bioactive constituents in cancer therapy and radioprotection. This review consolidates the most recent relevant data on turmeric’s chemical composition and its therapeutic applications, providing a comprehensive overview of its potential in cancer prevention and treatment, as well as in radioprotection.
Numerous interventional studies have revealed the beneficial impact of curcumin supplementation on inflammation, oxidative stress, and endothelial function biomarkers, but the findings are still inconsistent. Thus, this study was conducted to investigate the effects of curcumin supplementation on inflammation, oxidative stress, and endothelial function biomarkers. A meta-analyses of randomized clinical trials was performed by searching PubMed, Embase, Scopus, and Web of Science up to March 31, 2024. Pooled estimates of 21 meta-analyses revealed that curcumin significantly reduced CRP (weighted mean difference (WMD) = -0.87; 95 % CI: - 1.14, - 0.59, P< 0.001), tumor-necrosis factor-alpha (TNF-α) (WMD = -2.72; 95 % CI: -4.05, -1.38; P< 0.001), interleukin-6 (IL-6) (WMD = -0.97, 95 % CI: -1.40, -0.54; P< 0.001), malondialdehyde (MDA) (Effect size (ES) = -0.81; 95 % CI: -1.39, -0.23, P = 0.006) and pulse wave velocity (PWV) (WMD = -45.60; 95 % CI: -88.16, -3.04, P = 0.036), and increased flow-mediated dilation (FMD) (WMD = 1.64, 95 % CI: 1.06, 2.22, P < 0.001), catalase (CAT) (WMD = 10.26; 95 % CI: 0.92, 19.61, P= 0.03), glutathione peroxidase (GPx) (WMD = 8.90; 95 % CI: 6.62, 11.19, P <0.001), and superoxide dismutase (SOD) levels (WMD = 20.51; 95 % CI: 7.35, 33.67, P= 0.002 and SMD = 0.82; 95 % CI: 0.27, 1.38, P= 0.004). However, curcumin did not significantly change total antioxidant capacity (TAC) (ES = 0.29; 95 % CI: -0.09, 0.66, P= 0.059). These results suggest that curcumin has a beneficial effect on CRP, IL-6, TNF-α, SOD, GPx, CAT, MDA, PWV, and FMD levels and may be an effective adjunctive therapy for improving inflammation, oxidative stress, and endothelial function. Registration number: PROSPERO, CRD42024539018.
Metabolic syndrome (MetS) and its associated conditions, namely, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), obesity, and polycystic ovary syndrome (PCOS) are characterized by insulin resistance, dyslipidemia, and low-grade inflammation. Curcumin, a polyphenolic compound derived from Curcuma longa Linn., exhibits pleiotropic metabolic and anti-inflammatory properties and has thus been evaluated as a nutraceutical intervention for these conditions, but findings remain inconsistent. This systematic review and meta-analysis evaluated the clinical efficacy of Curcuma longa supplementation on anthropometric, glycemic, lipid, inflammatory, and oxidative stress parameters in adults with MetS or related disorders. A comprehensive search of databases (PubMed, Scopus, AMED, LILACS, and Google Scholar) identified 104 eligible randomized controlled trials (RCTs). The included trials primarily assessed standardized oral turmeric/curcumin supplements and bioavailability-enhanced formulations rather than whole culinary turmeric. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were computed using random-effects models. Subgroup analyses were conducted by disease category, dose, and formulation. Risk of bias was assessed using the Cochrane RoB 2 tool. Curcumin supplementation significantly reduced fasting blood sugar (SMD = −0.54, 95% CI −0.72 to −0.36) and HbA1c (SMD = −0.41, 95% CI −0.60 to −0.23) in T2DM; decreased triglycerides (SMD = −0.48; 95% CI: −0.70 to −0.25), and LDL cholesterol (SMD = −0.39; 95% CI: −0.59 to −0.18) while elevating HDL cholesterol (SMD = 0.45; 95% CI: 0.25 to 0.65) and total antioxidant capacity (SMD = 0.73; 95% CI: 0.51 to 0.94). Curcuma longa also attenuated systemic inflammation, lowering C-reactive protein (SMD = −0.62; 95% CI: −0.81 to −0.43), TNF-α (SMD = −0.57; 95% CI: −0.80 to −0.34), and IL-6 (SMD = −0.50; 95% CI: −0.70 to −0.29). Heterogeneity was moderate-to-high, reflecting some d
This systematic review and meta-analysis evaluated the clinical efficacy of Curcuma longa supplementation on anthropometric, glycemic, lipid, inflammatory, and oxidative stress parameters in adults with MetS or related disorders. A comprehensive search of databases (PubMed, Scopus, AMED, LILACS, and Google Scholar) identified 104 eligible randomized controlled trials (RCTs). The included trials primarily assessed standardized oral turmeric/curcumin supplements and bioavailability-enhanced formulations rather than whole culinary turmeric. Pooled standardized mean differences (SMDs) with 95% confidence intervals (CIs) were computed using random-effects models.
Inflammatory Parameters The compelling evidence of the inflammatory parameters analyzed is a strong indication of the anti-inflammatory effects of Curcuma longa supplementation, which is a core of the mechanism of its effect on Metabolic Syndrome (MetS). The majority of the eligible Randomized Controlled Trials (RCTs) had a significant reduction in the most important inflammatory markers, which supports its contribution to the prevention of chronic low-grade inflammation, which is the pathology of MetS ( Supplementary Table S8 ).
These consistent CRP reductions across several populations indicate curcumin exerts an anti-inflammatory effect that is measurable through lower CRP. The funnel/Egger’s tests did not indicate publication bias for these CRP pools. TNF-α pooled effects were larger but heterogeneous. In diabetes cohorts (3 studies; 246 vs. 248) pooled SMD was −1.07 (95% CI −2.05 to −0.09), p < 0.05, suggesting a large point estimate reduction; however, heterogeneity was extreme (I 2 ≈ 91%, p < 0.01), and the Egger’s test suggested funnel asymmetry, raising concern for bias and instability in the pooled estimate ( Supplementary Figure S18 ).
Overall, oxidative biomarkers show heterogeneous and imprecise effects; although some trials report antioxidant improvements, the pooled evidence is inconsistent. Across the pooled randomized trials, curcumin/ Curcuma longa supplementation showed consistent small anti-inflammatory effects (notably reductions in CRP) and modest improvements in some glucose metrics (HbA1c, certain glucose measures) and HDL in selected populations. Signals for SBP/DBP reductions are present primarily in metabolic syndrome subgroups.
Outcome Domain Parameter Pooled SMD (95% CI) p -Value I 2 (%) Remarks Anthropometry BMI −0.27 (−0.57 to 0.02) >0.05 79 No significant effect; heterogeneous results Waist Circumference (WC) −0.33 (−0.81 to 0.15) >0.05 75 Non-significant; trend toward reduction Waist–Hip Ratio (WHR) −0.11 (−0.37 to 0.15) >0.05 60+ No effect Blood Pressure Systolic BP (SBP) −0.65 (−1.21 to −0.08) <0.05 65 Significant SBP reduction (mainly in MetS) Diastolic BP (DBP) −0.40 (−0.79 to −0.01) <0.05 63 Mild DBP reduction; modest heterogeneity Glycemic Control Fasting Blood Sugar (FBS) −0.25 (−0.48 to −0.03) <0.05 55 Small but significant reduction Blood Glucose −0.53 (−0.82 to −0.23) <0.05 58 Moderate improvement HbA1c −0.33 (−0.58 to −0.09) <0.05 66 Significant improvement in long-term control Insulin Function HOMA-IR −0.01 (−0.78 to 0.76) >0.05 95 No consistent effect; highly heterogeneous HOMA-B 0.09 (−0.19 to 0.36) >0.05 0 No effect on β-cell function QUICKI 0.41 (−0.39 to 1.21) >0.05 80+ Non-significant; high variability Serum Insulin −0.33 (−0.77 to 0.11) >0.05 75 No consistent
7. Conclusions The findings endorse curcumin as an adjunctive treatment for those with MetS, T2DM, NAFLD, or obesity. The pooled evidence from RCTs indicates that curcumin supplementation yields consistent anti-inflammatory effects and modest yet clinically meaningful improvements in glycemic regulation and selected lipid parameters in individuals with metabolic syndrome and related disorders. These benefits are most pronounced with bioavailability-enhanced curcumin formulations, underscoring the importance of formulation in determining therapeutic efficacy.
Abstract
Objectives
Migraine is a repeated, chronic and neurovascular disease that adversely affects the quality of life and increases the risk of cerebral lesion. Curcumin, the orange-yellow substance of turmeric, may possess anti-headache performance according to several studies. Thus, this study set out to meta-analytically access the anti-headache effect of curcumin supplementation in patients with migraine.
Methods
Five databases were searched as of September 30, 2022 to identify all eligible randomized controlled trials. The random-effect Hunter-Schmidt model was used to calculate the effect sizes based on the heterogeneity. The PROSPERO registration number for this meta-analysis is CRD42023409829 (
https://www.crd.york.ac.uk/PROSPERO/
).
Results
Four studies involving 170 patients finally met our inclusion criteria. In the results, curcumin supplementation showed a significant difference in the severity of migraine symptoms compared with placebo (Hedges’s g= -0.75, 95% confidence interval (CI) =-1.44 to -0.07,
P
= 0.03).
Conclusions
Curcumin supplementation may relieve the severity of headache symptoms in migraine sufferers.
<h4>Background</h4>Although curcumin has well-established anti-inflammatory and antioxidant qualities, its low bioavailability limits its therapeutic applicability. Piperine improves systemic exposure and absorption of curcumin. This systematic study aimed to examine the effectiveness and safety of curcumin-piperine supplementation in relation to inflammatory, metabolic, cardiovascular, autoimmune, infectious, and pulmonary disorders.<h4>Methods</h4>From 2026, a comprehensive search of randomised controlled trials (RCTs) was conducted across the main electronic databases. Studies that assessed oral curcumin in combination with piperine and reported results related to oxidative stress, inflammation, metabolism, cardiovascular disease, or clinical symptoms were considered eligible. Using accepted methodological standards, the risk of bias was evaluated.<h4>Results</h4>There were 20 RCTs with sample sizes ranging from 8 to 117 individuals and durations ranging from 1 to 12 weeks. Doses of piperine (5-15 mg/day) and curcumin (500-1,500 mg/day) varied. Fifteen out of twenty trials indicated significant decreases in inflammatory biomarkers [C-reactive protein (CRP), high-sensitivity CRP (hs-CRP), and interleukin-6 (IL-6)]. Of 15 studies evaluating these outcomes, 12 showed improvements in oxidative stress markers, including superoxide dismutase (SOD), total antioxidant capacity (TAC), and malondialdehyde (MDA). Supplementation dramatically decreased fasting blood glucose (FBS), glycated haemoglobin (HbA1C), and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) in individuals with metabolic syndrome (MetS) and type 2 diabetes. At the same time, 14 out of 18 trials showed reductions in lipid markers (triglycerides (TG), LDL-C, total cholesterol, and HDL-C). After coronary artery bypass grafting and acute myocardial infarction (AMI), cardiovascular populations showed decreases in cardiac damage biomarkers (CK-MB, AST, and ALT). COVID-19, premenstrual syndrome (PMS), dysmenorrhea, and chronic pulmonary illness all showed symptom-based improvements. No significant adverse effects were noted. None of the trials was high risk; 13 had low risk of bias, and 6 had moderate issues.<h4>Conclusion</h4>In a variety of clinical populations, curcumin-piperine supplementation consistently demonstrates anti-inflammatory, antioxidant, metabolic, and cardioprotective effects, with a good safety profile. Its utility as an adjuvant in metabolic and cardiometabolic illnesses is most strongly supported by evidence. To verify clinical efficacy and improve dosing techniques, larger, longer-term RCTs with standardized objectives are necessary.
red to be one of the natural compounds with the greatest potential in the treatment of diseases. The anti-inflammatory mechanism and therapeutic effect of curcumin are the research hotspots. This paper will review the current studies on the anti-inflammatory mechanism of curcumin, curcumin in the treatment of inflammatory bowel disease, arthritis and other diseases, and analyze the relevant studies on improving pharmacokinetics, in order to provide suggestions for further research and application of curcumin in the anti-inflammatory effect. Anti-Inflammatory Mechanism of Curcumin
The inflammatory pathway consists of four parts: inducers, sensors, mediators and effectors. The physiological and pathological mechanisms of inflammation caused by different Inflammatory triggers are different and have not yet been clarified. 7 In general, anti-inflammatory effects of drugs mainly include: acting on receptors and signaling pathways, regulating the response of target tissues to inflammatory mediators; reversing the effect of the medium on the target tissue; produce anti-inflammatory mediators and so on. 6 Curcumin exerts anti-inflammatory effects by regulating inflammatory signaling pathways and inhibiting the production of inflammatory mediators ( Figure 2 ).
Figure 2.
Open in a new tab
The regulatory effect of curcumin on inflammatory signaling pathway. Curcumin binds to Toll-like receptors (TLRs) and regulates downstream nuclear factor kappa-B (NF-κB), Mitogen-activated protein kinases (MAPK), Activator Protein 1(AP-1) and other signaling pathways, 8–10 thereby regulating inflammatory mediators and treating inflammatory diseases. Curcumin can down-regulate NF-κB through acting on Peroxisome proliferator-activated receptor gamma (PPARγ). 11 , 12 Curcumin can also play anti-inflammatory effects by regulating The Janus kinase/Signal transducer and activator of transcription (JAK/STAT) inflammatory signaling pathway. 13 , 14 In addition, NOD-like receptor pyrin domain-contai
chemo treatments. —An herbal anti-inflammatory to reduce swelling: turmeric (curcumin) or Crystal Star … and uterine fibroids, with significant anti-inflammatory and anti-scarring effects. 3: Sea greens and bone … rosemary, oregano and anti-aging nutrients are another high quality choice. ... Turmeric: a powerful antioxidant
say that turmeric is a safe and effective digestive aid. The active ingredients in turmeric are not water … and less animal fats. Anti-Inflammatory Herbs Numerous herbs have anti-inflammatory properties, but instead … formula contains such well-researched anti-inflammatory herbs as turmeric, holy basil, oregano, rosemary, green
Everything we examined (10) — 9 independent sources
This check searched the claim as stated. It did not run a separate search for evidence against it.